ABBOTT LABORATORIES (ABT) 107.58 +2.58 (+2.46%)
107.58 +2.58 (+2.46%)
US0028241000 - Common Stock - After market: 107.4 -0.18 (-0.17%)
Fundamental Rating
Overall ABT gets a fundamental rating of 6 out of 10. We evaluated ABT against 221 industry peers in the Health Care Equipment & Supplies industry. ABT has a great profitability rating, but there are some minor concerns on its financial health. ABT is valued expensive and it does not seem to be growing.
Profitability
Profitability Rating
ABT has a Return On Assets of 10.84%. This is amongst the best returns in the industry. The industry average is -18.33%. ABT outperforms 92% of its industry peers.
ABT has a Return On Equity of 22.11%. This is better than the industry average of 10.59%.
ABT has a Profit Margin of 17.52%. This is amongst the best returns in the industry. The industry average is -28.67%. ABT outperforms 91% of its industry peers.
The Piotroski-F score of ABT is 9.00. This is a very strong score and indicates great health and profitability for ABT.
VS Industry
ROA (10.84%) VS Industry: 92% outperformed.
-771.54
117.69
ROE (22.11%) VS Industry: 80% outperformed.
0.69
140.68
Profit Margin (17.52%) VS Industry: 91% outperformed.
-142,068.42
1,450.19
Valuation
Valuation Rating
Compared to an average industry Price/Earning Ratio of 23.64, ABT is valued a bit cheaper than its industry peers.
The Price/Earnings Ratio is 19.11, which indicates a rather expensive current valuation of ABT.
With a Forward Price/Earnings Ratio of 23.01, ABT is valued rather expensively.
The PEG Ratio, which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
When comparing the current price to the book value of ABT, we can conclude it is valued correctly. It is trading at 5.26 times its book value.
Compared to an average industry Enterprise Value to EBITDA ratio of 12.19, ABT is valued in line with its industry peers.
Compared to an average industry price book ratio of 2.66, ABT is valued more expensive than its industry peers.
VS Industry
Price/Earnings (19.11) VS Industry: 63% outperformed.
1,904.64
0.04
Price/Book (5.26) VS Industry: 29% outperformed.
1,042.45
0.08
Enterprise Value/ EBITDA (14.63) VS Industry: 43% outperformed.
4,786.74
0.00
Growth
Growth Rating
ABT shows quite a strong growth in Earnings Per Share. Measured over the last 5 years, the EPS has been growing by 18.82% yearly.
The Revenue has been growing by 15.61% on average over the past 5 years. This is quite good.
The Earnings Per Share has been growing slightly by 5.43% over the past year.
The Earnings Per Share is expected to grow by 0.04% on average over the next 5 years.
ABT shows a small growth in Revenue. In the last year, the Revenue has grown by 6.43%.
The Revenue is expected to decrease by -1.32% on average over the next 5 years.
The EPS growth is decreasing: in the next 5 years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | 18.82% | 21.85% | 5.43% | -2.03% | -5.26% | -0.29% | 0.04% |
| Revenue | 15.61% | 12.1% | 6.43% | 2.19% | -3.56% | -0.66% | -1.32% |
Health
Health Rating
ABT has an Altman-Z score of 4.88. This indicates that ABT is financially healthy and little risk of bankruptcy at the moment.
ABT is in better financial health than average in its industry. Its Altman-Z score is much better than the industry average of 1.80.
The Piotroski-F score of ABT is 9.00. This is a very strong score and indicates great health and profitability for ABT.
ABT has a Current Ratio of 1.86. This is a normal value and indicates that ABT is financially healthy and should not expect problems in meeting its short term obligations.
A Quick Ratio of 1.43 indicates that ABT should not have too much problems paying its short term obligations.
When comparing the Current Ratio of ABT to the average industry Current Ratio of 3.66, ABT is less able to pay its short term obligations than its industry peers. 82% of its industry peers have a better Current Ratio.
Compared to an average industry Quick Ratio of 2.92, ABT is worse placed to pay its short term obligations than its industry peers.
Compared to an average industry Debt to Equity Ratio of 0.09, ABT is more dependent on financing than its industry peers.
VS Industry
Debt/Equity (0.43) VS Industry: 27% outperformed.
336.87
0.00
Quick Ratio (1.43) VS Industry: 24% outperformed.
0.06
31.22
Current Ratio (1.86) VS Industry: 18% outperformed.
0.13
31.22
Altman-Z (4.88) VS Industry: 73% outperformed.
-105.06
70.07
Dividend
Dividend Rating
Compared to an average industry Dividend Yield of 1.24, ABT pays a bit more dividend than its industry peers.
On average, the dividend of ABT grows each year by 17.13%, which is quite nice.
ABT has paid a dividend for at least 10 years, which is a reliable track record.
With a Yearly Dividend Yield of 1.81%, ABT has a reasonable but not impressive dividend return.
41.63% of the earnings are spent on dividend by ABT. This is a bit on the high side, but may be sustainable.
ABT's Dividend Yield is slightly below the S&P500 average, which is at 2.47.
ABT's earnings are declining while the Dividend Rate has been growing. This means the dividend growth is most likely not sustainable.
VS Industry
Dividend Yield (1.81%) VS Industry: 72% outperformed.
0.02
6.19
ABBOTT LABORATORIES107.58
NYSE:ABT (11/30/2022, 7:17:20 PM)+2.58 (+2.46%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Health Care Equipment & Services | ||
| GICS Industry | Health Care Equipment & Supplies | ||
| Earnings (Last) | 10-19 2022-10-19/bmo | Earnings (Next) | 01-24 2023-01-24 |
| Ins Owners | 0.7% | Inst Owners | 175.76% |
| Market Cap | 187.57B | Analysts | 78 |
| PE | 19.11 | Fwd PE | 23.01 |
| PEG (NY) | N/A | PEG (5Y) | 1.02 |
| P/S | 4.17 | P/B | 5.26 |
| EV/EBITDA | 14.63 | ||
| Dividend Yield | 1.81% | Dividend Growth | 17.13% |
| DP | 41.63% | Ex-Date | 10-13 2022-10-13 (0.47) |
| EPS 1Y | 5.43% | EPS 3Y | 21.85% |
| EPS 5Y | 18.82% | EPS growth Q2Q | -17.86% |
| EPS Next Y | -2.03% | EPS Next 2Y | -5.26% |
| EPS Next 3Y | -0.29% | EPS Next 5Y | 0.04% |
| Revenue growth 1Y | 6.43% | Revenue growth 3Y | 12.1% |
| Revenue growth 5Y | 15.61% | Revenue growth Q2Q | -4.74% |
| Revenue Next Year | 2.19% | Revenue Next 2Y | -3.56% |
| Revenue Next 3Y | -0.66% | Revenue Next 5Y | -1.32% |
| Current Ratio | 1.86 | Quick Ratio | 1.43 |
| Altman-Z | 4.88 | F-Score | 9 |
| Debt/Equity | 0.43 | WACC | 9.07% |
| ROIC/WACC | 5.7 | ||
| ROA | 10.84% | ROE | 22.11% |
| ROICexgc | 51.68% | ROIC | 14.26% |
| PM | 17.52% | OM | 21.31% |
| Asset Turnover | 0.62 | ||
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA